Dopamine transporter inhibitors for use in treatment of movement disorders and other CNS indications
申请人:Prexa Pharmaceuticals, Inc.
公开号:EP2338881A1
公开(公告)日:2011-06-29
The invention provides a class of dopamine transporter inhibitors of formula (I) (DAT inhibitors), packaged pharmaceuticals comprising such inhibitors, and their uses in treating, or the manufacturing medicaments for treating disease conditions, inlcuding Parlcinsora's disease, Hoehn and Yahr Staging of Parkinson's Disease, Unified Parkinson Disease Rating Scale (UPDRS), and Schwab and England Activities of Daily Living Scale. Related business methods such as marketing the inhibitors to healthcare providers are also provided.
本发明提供了一类式(I)的多巴胺转运体抑制剂(DAT抑制剂)、包含此类抑制剂的包装药品,以及它们在治疗疾病或制造治疗疾病药物中的用途,包括帕金森病、帕金森病的Hoehn和Yahr分期、统一帕金森病评分量表(UPDRS)以及Schwab和England日常生活活动量表。还提供了相关的商业方法,如向医疗保健提供商推销抑制剂。